id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-322332-0pi3wcv5	Conforti, Claudio	Doxycycline, a widely used antibiotic in dermatology with a possible anti‐inflammatory action against IL‐6 in COVID‐19 outbreak	2020-05-15		.txt	text/plain	511	37	40	An open-label nonrandomized clinical trial suggested that chloroquine and its less toxic metabolite, hydroxychloroquine, may be effective against COVID-19. In fact, in addition to its well-defined antibiotic effects (bacteriostatic action by inhibition of bacterial protein synthesis), in vitro studies have shown doxycycline to exert anti-inflammatory effects at low (20-40 mg/day) and high (100 or 200 mg/day) doses with inhibitory action on metalloproteases and modulating effects of pro-inflammatory cytokines IL-6, IL-8, and tumor necrosis factor-alpha. 7 The anti-inflammatory properties of doxycycline and other components of tetracycline has been demonstrated for several inflammatory airway diseases, including, acute respiratory distress syndrome. 8 Thereby, low doxycycline doses have been shown to be more effective than high doses to prevent induction of pro-inflammatory cytokines (such as IL-6) in inflammatory diseases. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	./cache/cord-322332-0pi3wcv5.txt	./txt/cord-322332-0pi3wcv5.txt